clinical trial · NCT00860600
Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients
Idiopathic Thrombocytopenic Purpura (ITP)PG2
brief summary
This was a phase II multi-center, randomized, open-label study with two parallel study groups to evaluate the efficacy and safety of PG2 in ITP patients.
started
Sep 1, 2008
primary completion
Aug 1, 2011
completion
Aug 1, 2011
last updated
Jun 4, 2025
detailed description
The primary objective of this exploratory study is to evaluate the efficacy of PG2 in raising the platelet counts in ITP patients using two dosing schedules. The secondary objective is to determine the safety of PG2 treatment among these patients.
official title
The Clinical Trial of PG2 in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol